Tiziana to initiate development of ‘Take Home’ nasal COVID treatment
Category: #health  By Pankaj Singh  Date: 2021-06-18
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This grant is related to an innovative ‘Take Home’ approach to advance the clinical development of Foralumab, a fully human, nasally administered, anti-CD3 monoclonal antibody, as a COVID treatment to cater to non-hospitalized infected patients. This move has been made in response to the UK government’s call to examine new therapies to ensure home treatment and avoid hospitalization of patients.

The nasal administration of the anti-CD3 monoclonal antibody can be considered a highly innovative approach to treat autoimmune diseases, where the immune system of the patients might be dysregulated. Various research studies have also identified the dysregulation of the immune system among COVID-infected patients.

Tiziana Life Sciences previously completed a clinical trial of Foralumab among patients with COVID-19 in Brazil. The clinical trial results demonstrated that the antibody can induce immunomodulatory effects and clinical benefits to the patients.

As evident from the CT scans & reduced systemic markers of lung inflammation such as interleukin-6 and C-reactive protein, the direct delivery of this treatment using the ‘Take Home’ nasal spray to the respiratory tract and nasal passage significantly suppressed the inflammation. These positive trial results are expected to lead to its further clinical development among coronavirus-infected patients.

Furthermore, the biotechnology company is set to initiate another clinical study among the COVID-19 hospitalized patients across Brazil. The main objective of the trial is to evaluate the effectiveness of this nasally administered treatment in these patients with severe inflammation. In addition, the ‘Take Home’ approach may also expand its scope for the treatment of other COVID variants, as the nasal administration of Foralumab is considered an immunomodulatory approach. These variants include those that were identified in Brazil, South Africa, the UK, as well as the Delta variant in India.

Source credit:

https://www.globenewswire.com/news-release/2021/06/17/2248638/0/en/Tiziana-Responds-to-UK-Call-for-Development-of-Innovative-Take-Home-Treatments-for-COVID-19-Disease.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Eargo collaborates with VARTA to power Eargo 5 hearing device

Eargo collaborates with VARTA to power Eargo 5 hearing device

By Pankaj Singh

Eargo, Inc., an American hearing aid manufacturer, has reportedly collaborated with VARTA AG, a battery maker, to power its recently launched hearing aid, Eargo 5. This medical-grade device is the smallest and most adv...

Target, Ulta Beauty divulge brand & location details ahead of Launch

Target, Ulta Beauty divulge brand & location details ahead of Launch

By Pankaj Singh

Leading retail firm, Target Corporation, along with Ulta Beauty, an American beauty store chain, has reportedly revealed insights on the much awaited Ulta Beauty at Target. The launch is slated to start this August acr...

Japan becomes first nation to sanction REGEN-COV™ for COVID-19 treatment

Japan becomes first nation to sanction REGEN-COV™ for COVID-19 treatment

By Pankaj Singh

Regeneron Pharmaceuticals Inc. has reportedly declared that the Ministry of Health, Labor, and Welfare (MHLW) of Japan has approved the company’s imdevimab and casirivimab antibody cocktail to treat COVID-19 pati...